Novartis' late-stage blockbuster push gets major boost with another 'breakthrough' for MET therapy
Novartis has just received a major boost in its race with Pfizer to develop a therapy for a notoriously treatment-resistant cancer and get one of its projected 2020 blockbuster drugs to market.
The FDA has expanded Novartis’ “breakthrough therapy” designation for capmatinib (INC280) to treat a particularly aggressive form of non-small cell lung cancer, MET exon14 skipping-mutated NSCLC. Pfizer achieved breakthrough therapy designation to treat the same disease with Xalkori (crizotinib), which is already in use to treat less-resistant forms of NSCLC, in March of 2018. No known treatment is currently approved for the ailment.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
